ArticleInternational journal of clinical and experimental pathology2017
miR-125b expression affects tumor growth of multiple myeloma via targeting MKK7.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- RNA-Based Therapeutic Strategies in Multiple Myeloma: From Molecular Targets to Delivery and Clinical Translation.International journal of molecular sciences · 2026Review
- Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many miRNAs are reported to be involved in tumor development. The underlying mechanism of miRNAs driving multiple myeloma (MM) progress remains elusive. This study is to investigate the effect of miR-125b, a brain-enriched microRNA, on mitogen-activated protein kinase 7 (MKK7) in vivo. We found significantly up-regulation of miR-125b and deregulation of MKK7 in MM. The inverse correlation was further confirmed in multiple myeloma samples and cell lines. In addition, MKK7 was identified as a downstream target gene of miR-125b, which could bind to the 3' UTR of MKK7. Overexpression of miR-125b was associated with decreased MKK7 expression and miR-125b antagonisminhibited cell proliferation and clonogenicity. Taken together, our results demonstrated that MKK7 could function as an important tumor suppressor neutralized by miR-125b in MM, suggesting that miR-125b may be a novel potential molecular therapeutic target in the treatment of MM.
Indexed as
Identifiers
31966701PMC6965470W3026441678What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.